

CITATION REPORT

List of articles citing

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut

DOI: 10.7326/0003-4819-110-1-35

Annals of Internal Medicine, 1989, 110, 35-50.

Source: <https://exaly.com/paper-pdf/21027542/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
203	Medical Therapy of VIPomas. 1989 , 18, 545-556		46
202	VIP: molecular biology and neurobiological function. 1989 , 3, 201-36		214
201	OCTREOTIDE. 1989 , 334, 541-542		1
200	Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. 1989 , 38, 658-702		88
199	Octreotide: a long-acting somatostatin analog. 1990 , 300, 267-73		10
198	Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. 1990 , 11, 138-42		190
197	Regulatory Peptides in Renal Failure: Effects and Possible Pathophysiological Role. 1990 , 13, 149-161		4
196	Acromegaly. 1990 , 322, 966-77		481
195	Acromegaly and primary amenorrhea: ovulation and pregnancy induced by SMS 201-995 and bromocriptine. 1990 , 13, 193		32
194	All aboard for octreotide. 1990 , 336, 909-911		10
193	Gastrointestinal hormones: from basic science to a clinical perspective. 1990 , 60, 575-8		5
192	The clinical use of somatostatin analogues in the treatment of cancer. 1990 , 4, 29-49		26
191	Inhibitory effect of the somatostatin analog octreotide on rat pituitary tumor cell (GH3) proliferation in vitro. 1990 , 13, 657-62		19
190	Role of somatostatin and its analogues in the pathogenesis and treatment of diabetes mellitus. 1990 , 39, 52-4		19
189	Invasion and metastasis: biology and clinical potential. 1991 , 52, 235-44		24
188	Treatment of necrolytic migratory erythema in glucagonoma syndrome. 1991 , 25, 925-8		41
187	Four year treatment with a long acting somatostatin analogue in a patient with Verner-Morrison syndrome. 1991 , 14, 685-9		4

186	The therapeutic role of octreotide in the management of surgical disorders. 1991 , 162, 499-507	16
185	Acute pancreatitis following octreotide withdrawal. 1991 , 90, 763-764	13
184	Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. 1991 , 64, 451-6	66
183	The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells. 1991 , 64, 23-8	36
182	The paradoxical effects of somatostatin on the bioactivity and production of cytotoxins derived from human peripheral blood mononuclear cells. 1991 , 64, 243-6	10
181	Somatostatin and analogues in the treatment of cancer. A review. 1991 , 213, 190-8	55
180	Neuropeptide growth factors. 1991 , 9, 659-73	8
179	Effects of somatostatin analog SMS 201-995 on enterotoxigenic diarrhea. 1991 , 36, 1768-73	3
178	Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. 1991 , 325, 1461-7	324
177	Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide. 1991 , 67, 466-8	8
176	Aspects on diagnosis and treatment of the foregut carcinoid syndrome. 1992 , 27, 459-71	26
175	The effect of somatostatin analogue SMS 201-995 on serotonin levels in the medium of primary carcinoid cell cultures. 1992 , 27, 1077-83	5
174	Octreotide in the Treatment of Disorders of the Gastrointestinal System. 1992 , 4, 1-54	42
173	Suppression of superoxide release from human monocytes by somatostatin-related peptides. 1992 , 41, 39-47	38
172	Gallstones during octreotide therapy. 1992 , 41, 22-33	62
171	Endocrine applications of the somatostatin analogue octreotide (Sandostatin). 1992 , 41, 34-8	9
170	Looking ahead. 1992 , 41, 121-128	5
169	Improvement in survival of mice with proximal small bowel obstruction treated with octreotide. 1992 , 163, 231-3	8

168	Rheumatologic and Skeletal Changes in Acromegaly. 1992 , 21, 615-631	46
167	Effect of somatostatin analog octreotide on human sphincter of Oddi. 1992 , 37, 773-7	73
166	Postprandial gallbladder motility and plasma cholecystokinin at regular time intervals after injection of octreotide in acromegalics on long-term treatment. 1992 , 37, 1685-90	9
165	Effect of small doses of somatostatin analog, octreotide, on gallbladder contractility in normal Chinese adults. 1992 , 37, 105-8	7
164	Results of continuous long-term intravenous application of octreotide via an implantable pump system in acromegaly resistant to operative and X-ray therapy. 1992 , 117, 160-5	4
163	Somatostatin and growth hormone regulation in cancer. 1992 , 4, 31-6	13
162	A prospective examination of octreotide-induced gall-bladder changes in acromegaly. 1992 , 36, 265-9	14
161	Failure of somatostatin analogue to control Cushing's syndrome in two cases of ACTH-producing carcinoid tumours. 1992 , 36, 361-7	27
160	Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth?. 1992 , 51, 195-203	74
159	Persistent or recurrent acromegaly. Long-term endocrinologic efficacy and neurologic safety of postsurgical radiation therapy. 1992 , 69, 271-5	42
158	Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. 1993 , 71, 2624-30	238
157	Palliative treatment of neuroendocrine tumors. 1993 , 9, 453-8	3
156	Cholescintigraphic study of effect of somatostatin analog, octreotide, on bile secretion and gallbladder emptying in normal subjects. 1993 , 38, 1718-21	9
155	Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. 1993 , 38, 309-15	19
154	Inhibition of recombinant human growth hormone-induced and prolactin-induced activation of neutrophils by octreotide. 1993 , 347, 336-41	19
153	Somatostatin analog treatment of pancreatic fistulas. 1993 , 14, 181-8	20
152	Use of octreotide acetate for control of symptoms in patients with islet cell tumors. 1993 , 17, 504-10	45
151	Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. 1993 , 17, 511-9	73

150	Effect of (S)-Fluoromethylhistidine and SMS 201-995 on growth of histamine-producing gastric carcinoid of <i>Mastomys natalensis</i> . 1993 , 38, C158-C160	
149	Biology and management of the midgut carcinoid. 1993 , 165, 288-97	48
148	Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. 1993 , 25, 375-91	85
147	Inhibition of IGF-I and b-FGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. 1993 , 48, 267-78	79
146	Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide. 1993 , 47, 307-18	22
145	Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues. 1993 , 34, 1351-6	6
144	Somatostatin analogue phase I trials in neuroendocrine neoplasms. 1993 , 32, 217-23	95
143	Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. 1993 , 32, 225-9	191
142	Correlation between gall bladder fasting volume and postprandial emptying in patients with gall stones and healthy controls. 1993 , 34, 1443-7	42
141	Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. 1993 , 105, 1705-9	71
140	Octreotide in the treatment of refractory diarrhoea and intestinal fistulae. 1994 , 35, S5-10	20
139	Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. 1994 , 81, 10-4	35
138	Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. 1994 , 21, 561-81	123
137	The long-acting somatostatin analogue octreotide alleviates symptoms by reducing posttranslational conversion of prepro-glucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth. 1994 , 72, 127-33	14
136	Expanding uses of octreotide. 1994 , 8, 321-37	6
135	Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study. 1994 , 39, 2384-8	15
134	Metabolic remission with octreotide in patients with insulinoma. 1994 , 235, 245-8	18
133	Intraocular transplantation and primary cell cultures as experimental models for the study of human carcinoid disease. 1994 , 733, 380-92	3

132	Gut hormones and intestinal function. 1994 , 8, 137-64	10
131	Neuroendocrine tumors of the pancreas and duodenum. 1994 , 31, 77-156	94
130	Somatostatin: physiology and clinical applications. 1994 , 8, 215-36	41
129	Insulin resistance--not hyperinsulinemia--is pathogenic in essential hypertension. 1994 , 42, 226-36	10
128	The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. 1994 , 107, 1503-13	61
127	Adverse effects of drugs used in the management of constipation and diarrhoea. 1994 , 10, 47-65	98
126	Nonsurgical closure of esophago-respiratory fistulas: role for the somatostatin analogue octreotide acetate?. 1994 , 308, 152-6	3
125	Effect of octreotide on circulating IGF-I chromatographic profile: evidence for an inhibitory action on the formation of the 150-kDa ternary complex. 1995 , 42, 161-7	11
124	Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. 1995 , 237, 269-75	33
123	Neuroendocrine metastases of the liver. 1995 , 19, 76-82	69
122	Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. 1995 , 40, 1464-73	57
121	¹¹¹ In-octreotide scintigraphy: a tool to select patients with endocrine pancreatic tumors for octreotide treatment?. 1995 , 9, 149-52	0
120	From motilin to motilides: a new direction in gastrointestinal endocrinology. 1995 , 1, 179-84	0
119	Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. 1995 , 108, 1753-60	55
118	Serotonin, catecholamines, and spontaneous midgut carcinoid flush: plasma studies from flushing and nonflushing sites. 1995 , 108, 743-51	39
117	A prospective, double-blind trial of somatostatin analog (octreotide) versus glucagon for the inhibition of small intestinal motility during endoscopic retrograde cholangiopancreatography. 1995 , 42, 321-4	9
116	Evaluation of the adult patient with diarrhea. 1996 , 23, 629-47	3
115	In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. 1996 , 23, 1388-99	31

114	Gastrointestinal Endocrine Cancers and Nodal Metastasis: Biologic Significance and Therapeutic Implications. 1996 , 5, 159-171	10
113	The diagnostic utility of somatostatin receptor scintigraphy in oncology. 1996 , 122, 513-32	20
112	Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. 1996 , 39, 279-83	155
111	Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. 1996 , 38, 430-8	255
110	TSH-Secreting Pituitary Adenoma: Current Management and Review. 1997 , 7, 89-93	2
109	Effect of octreotide on human sphincter of Oddi motility following liver transplantation. 1997 , 42, 1168-75	4
108	[Carcinoid syndrome. Recurrent upper abdominal pain, diarrhea and flush in a 15-year-old girl]. 1997 , 92, 739-43	1
107	Gastrointestinal carcinoid tumors: current management strategies. 1997 , 40, 1101-18	63
106	The adverse effects of octreotide on the healing of colonic anastomoses in rats. 1998 , 28, 279-84	14
105	Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. 1998 , 77, 632-7	94
104	Metastatic melanoma of the nasal cavity in a patient with oculocutaneous albinism. 1998 , 10, 404-6	5
103	Slow-release lanreotide treatment in endocrine gastrointestinal tumors. 1998 , 93, 1468-71	71
102	The cost-effectiveness of octreotide acetate in the treatment of carcinoid syndrome and VIPoma. 1998 , 14, 514-25	8
101	Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. 1999 , 17, 600-6	317
100	Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. 1999 , 10 Suppl 2, S31-8	86
99	[111In-DPTA-D-Phe1]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma. 1999 , 14, 59-64	26
98	Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. 2000 , 14, 557-60	97
97	Somatostatin and octreotide stimulate short-circuit current in human colonic epithelium. 2000 , 45, 2100-7	2

96	The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. 2000 , 95, 3276-81	159
95	Synthesis, characterization, and biological properties of cyanine-labeled somatostatin analogues as receptor-targeted fluorescent probes. 2001 , 12, 44-50	100
94	The Role of Somatostatin and Octreotide in Bowel Obstruction: Pre-Clinic AI and Clinical Results. 2001 , 87, 1-9	27
93	AUTONOMIC DISORDERS. 2001 , 7, 220-233	5
92	Vipoma: effective treatment with octreotide in the oldest old. 2001 , 49, 496-7	6
91	Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases. 2001 , 4, 135-43	4
90	Effect of octreotide on small intestinal motility in HIV-infected patients with chronic refractory diarrhea. 2001 , 46, 2636-42	5
89	Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. 2002 , 3, 643-56	48
88	Somatostatin analogs and radiopeptides in cancer therapy. 2002 , 66, 161-83	115
87	Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. 2002 , 94, 331-43	181
86	Effect of octreotide on fluid absorption and secretion by the normal human jejunum and ileum in vivo. 2002 , 16, 769-77	21
85	Neuroendocrine tumours of the pancreas. 2000 , 87, 129-31	64
84	Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. 2001 , 88, 190-9	116
83	Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. 2003 , 17, 437-44	63
82	Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. 2003 , 18, 601-9	37
81	Severe and prolonged hypoglycemia triggered by long-acting octreotide in a patient with malignant mesenchymal tumor: case report. 2003 , 15, 85-8	3
80	Octreotide-sensitive ectopic ACTH production by islet cell carcinoma with multiple liver metastases. 2003 , 50, 135-43	16
79	Systemic complications of acromegaly: epidemiology, pathogenesis, and management. 2004 , 25, 102-52	880

78	Unlabelled somatostatin analogues in treatment of digestive endocrine tumours. 2004 , 36 Suppl 1, S42-7	3
77	Chromogranin A as a determinant of midgut carcinoid tumour volume. 2004 , 120, 269-73	33
76	Pancreatic endocrine tumors. 2004 , 120, 139-61	127
75	Malignant insulinoma: spectrum of unusual clinical features. 2005 , 104, 264-72	128
74	Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. 1994 , 81, 1144-9	37
73	Should interferon- α and somatostatin analogs be combined in gastroenteropancreatic neuroendocrine tumor therapy?. 2005 , 2, 229-235	
72	Rare functioning pancreatic endocrine tumors. 2006 , 84, 189-95	104
71	Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors. 2006 , 17, 601-8	36
70	Successful treatment of insulinoma by a single daily dose of octreotide in two elderly female patients. 2006 , 53, 79-85	14
69	Rationale for the use of somatostatin analogs as antitumor agents. 2006 , 17, 1733-42	214
68	Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?. 2007 , 18, 13-19	70
67	Tumeurs endocrines digestives. 2007 , 2, 1-14	1
66	Review article: anti-diarrhoeal pharmacology and therapeutics. 2007 , 9, 86-106	2
65	Long-acting octreotide as rescue therapy in chronic bleeding from gastrointestinal angiodysplasia. 2007 , 26, 935-42	52
64	Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. 2008 , 68, 904-11	41
63	Therapeutic strategies in the management of endocrine GEP tumours. 1990 , 20 Suppl 1, S82-90	8
62	Postprandial exocrine pancreatic function during long-term treatment with the somatostatin analogue SMS 201-995 in acromegalic patients. 1990 , 20, 348-53	4
61	[Therapeutic possibilities in patients with [selective pituitary resistance to thyroid hormones]. 2008 , 130, 345-50	2

60	Future clinical prospects in somatostatin/cortistatin/somatostatin receptor field. 2008 , 286, 262-77	20
59	Insulinoma. 2009 , 89, 1105-21	72
58	Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone-releasing hormone in normal subjects. 2010 , 40, 379-382	2
57	Cholelithiasis and acromegaly: therapeutic strategies. 1994 , 40, 401-6	32
56	Duodeno-pancreatic neuroendocrine tumours. 2010 , 19, 393-402	
55	Role of Somatostatin Analogs in the Management of Neuroendocrine Tumors. 2010 , 96, 191-197	
54	Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. 2010 , 139, 742-53, 753.e1	135
53	Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. 2010 , 36 Suppl 3, S87-94	31
52	The role of angiogenesis in neuroendocrine tumors. 2010 , 39, 839-52	6
51	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. 2011 , 17 Suppl 4, 1-44	178
50	Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula. 2011 , 23, 912-22	24
49	Insulinoma and anaesthetic implications. 2012 , 56, 117-22	5
48	Circulating Biomarkers of Response to Sunitinib in Gastroenteropancreatic Neuroendocrine Tumors. 2012 , 16, 151-161	12
47	Pancreatic neuroendocrine tumors. 2013 , 50, 509-45	46
46	Somatostatin analogues for treatment of enterocutaneous fistula. 2013 ,	3
45	Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. 2014 , 32, 1006-11	27
44	WITHDRAWN: Current Problems in Surgery: Pancreatic Neuroendocrine Tumors. 2014 ,	
43	Tratamiento de la acromegalia: presente y futuro. 2015 , 121-134	

42	Successful use of long-acting octreotide for intractable chronic gastrointestinal bleeding in children. 2015 , 60, 48-53	7
41	Management of Asymptomatic Gallstones. 2015 , 67-75	0
40	Insulinoma pancreático: casuística de um hospital central e revisão da literatura. 2016 , 11, 181-187	
39	Roles of Methylated DNA Biomarkers in Patients with Colorectal Cancer. 2019 , 2019, 2673543	19
38	Surgical-pharmacological interactions in the treatment of acromegaly. 2019 , 14, 35-42	3
37	Tumeurs endocrines digestives et pancréatiques. 2006 , 219-240	1
36	Chemotherapy of Advanced Thyroid Cancer. 1992 , 204-214	2
35	Growth factors and lung cancer. 1995 , 72, 111-30	2
34	GI Hormone Producing Tumours: Syndromes and Treatment Options. 2004 , 31-53	1
33	Therapeutic Use of Somatostatin and Octreotide Acetate in Neuroendocrine Tumors. 1992 , 55-66	1
32	Multiple Endocrine Neoplasia. 2016 , 1723-1761.e3	1
31	Multiple Endocrine Neoplasia. 2011 , 1728-1767	6
30	NONANTIBIOTIC THERAPY AND PHARMACOTHERAPY OF ACUTE INFECTIOUS DIARRHEA. 1993 , 22, 683-707	6
29	The Role of Surgery in the Management of Islet Cell Tumors. 1989 , 18, 805-830	42
28	The Use of the Long-Acting Somatostatin Analogue, Octreotide Acetate, in Patients with Islet Cell Tumors. 1989 , 18, 897-922	49
27	Clinical uses of gut peptides. 1997 , 225, 145-54	11
26	Somatostatin in gastroenterology. 1994 , 308, 1381-2	4
25	Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumors. 1997 , 2, 50-58	27

- 24 Wachstum. **2001**, 3-28
- 23 The Endocrine Pancreas. **2002**, 99-164
- 22 Carcinoid Tumors. **2003**,
- 21 Should interferon- and somatostatin analogs be combined in gastroenteropancreatic neuroendocrine tumor therapy?. **2005**, 2, 229-235
- 20 Introduction. 1-6
- 19 Opportunistic Infections. **2009**, 531-571
- 18 CONDITION OF THE MUSCULOSKELETAL SYSTEM IN PATIENTSWITH ACROMEGALY.. **2010**, 13, 19-27
- 17 Somatostatin in the Treatment of Acromegaly. **1991**, 269-276
- 16 Polyamines and Growth Factors as Possible Targets for Antitumor Therapy in Breast Cancer. **1992**, 291-299
- 15 Tumours of the Endocrine Glands. **1992**, 269-281
- 14 New Endocrine Agents for Breast Cancer. **1992**, 45-52
- 13 CHEMOTHERAPY IN THE MANAGEMENT OF MALIGNANT GASTROINTESTINAL DISEASE. **1992**, 21, 695-714
- 12 USE OF GUT PEPTIDE RECEPTOR AGONISTS AND ANTAGONISTS IN GASTROINTESTINAL DISEASES. **1992**, 21, 551-566 2
- 11 The Small Intestine: Normal Structure and Function. **1993**, 1-5 1
- 10 Effects of Somatostatin and Octreotide on Pancreatic Function. **1993**, 691-702
- 9 Somatostatin Analogue Therapy of Neuro-Endocrine Gastro-Entero Pancreatic Tumors. **2004**, 251-270
- 8 Thyrotropin-secreting Pituitary Adenomas. **2008**, 237-270 1
- 7 Traitement antisécrétoire des tumeurs endocrines. **2008**, 195-213

6	Occult retroperitoneal carcinoid tumor with flushing and solitary lung metastasis. 1989 , 151, 461-3	4
5	Somatostatin analogue (octreotide) inhibits bile duct epithelial cell proliferation and fibrosis after extrahepatic biliary obstruction. 1993 , 143, 1574-8	32
4	Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. 2012 , 16, 151-61	5
3	Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies.. <i>Drugs and Aging</i> , 2022 , 39, 257	4-7
2	Pedobarography May Play a Role in Foot Plantar Scanning in Acromegaly. <i>International Journal of Clinical Practice</i> , 2022 , 2022, 1-7	2.9
1	Cystic presentation of primary hepatic neuroendocrine tumour: a case report with a brief review of literature. 266-272	0